AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement
AVITA Medical, Inc. submits response to FDA for additional information on RECELL GO™, positioning for FDA approval on May 30, 2024, and product launch on May 31, 2024. CEO Jim Corbett anticipates broader adoption of RECELL with the new product.
The submission of the PMA supplement for RECELL GO™ by AVITA Medical to the FDA is a strategic move that could significantly expand the company's market share within the regenerative medicine sector. The Breakthrough Devices Program expedites the development and review process for promising medical devices, which indicates a potential for RECELL GO™ to address unmet medical needs swiftly. The anticipated approval and subsequent product launch could catalyze AVITA's stock value, as investors often react positively to such advancements, especially when they promise to reduce costs, such as training expenses in this case and improve adoption rates.
From a market perspective, RECELL GO™ is poised to enhance the company's growth trajectory by simplifying the use of its technology, which could lead to increased sales and market penetration. Furthermore, the device's ability to reduce the training burden on medical professionals suggests a lower barrier to entry, potentially resulting in broader adoption and increased recurring revenue streams for AVITA Medical.
The PMA supplement for RECELL GO™ under the FDA's Breakthrough Devices Program suggests that RECELL GO™ is considered a substantial improvement over existing therapies for wound care management and skin restoration. The device's potential to transform patient care by broadening the applications of RECELL technology may lead to improved patient outcomes and efficiency in medical procedures. The emphasis on reduced training burden for medical professionals indicates a user-friendly design, which is critical for the adoption of new medical technologies in clinical settings.
It is important to note that the successful adoption of RECELL GO™ hinges not only on FDA approval but also on the clinical evidence supporting its efficacy and safety. The data from in-house testing incorporated in the PMA supplement will be crucial in determining the device's market viability and acceptance within the medical community.
AVITA Medical's announcement of the expected FDA approval date for RECELL GO™ provides investors with a clear timeline for potential market impact. The company's stock performance may see short-term volatility leading up to the FDA's decision, with significant potential for appreciation upon approval. The 180-day real-time review period under the Breakthrough Devices Program suggests an accelerated path to market, which could give AVITA a competitive advantage.
Investors should consider the implications of the RECELL GO™ launch on AVITA's financials, including potential revenue growth and profit margins. The company's ability to launch the product immediately after FDA approval demonstrates operational readiness and confidence in their regulatory strategy. However, it is essential to monitor the post-launch adoption rate and any competitive responses that could influence AVITA's market position and financial outlook in the long term.
02/29/2024 - 04:02 PM
VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced it has submitted its response to the U.S. Food and Drug Administration (FDA) for additional information requested in connection to its premarket approval (PMA) supplement for RECELL GO™ . This submission resumes the substantive interactive review process under the Breakthrough Devices Program.
The response addresses various questions and incorporates data from in-house testing to support the PMA supplement and fulfil the additional information request, which we received in October of 2023. Upon receipt by the FDA, the application of the PMA supplement resumes its 180-day real time review, with 90 days remaining in the review period. Therefore, we expect FDA approval on May 30, 2024, positioning us for a product launch on May 31, 2024.
“RECELL GO will enhance our capabilities and reach to continue our already impressive growth,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “RECELL GO reduces the training burden on medical professionals and our field sales organization. In doing so, we anticipate broader adoption of RECELL across various applications, ultimately amplifying our impact and transforming patient care."
The supplement follows the original PMA of its RECELL Autologous Cell Harvesting Device and subsequent PMA supplements.
About AVITA Medical, Inc. ® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL® System, approved by the Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm® , a biosynthetic wound matrix, in the United States.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com .
Forward-Looking Statements Statements in this press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” and similar words or expressions, and the use of future dates. Forward-looking statements in this press release include but are not limited to statements concerning our product development activities and regulatory approval of our products. These statements are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the “Risk Factors” section of the Company’s latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.
Investor & Media Contact: investor@avitamedical.com media@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
AVITA Medical expects FDA approval for RECELL GO™ on May 30, 2024.
The response submitted by AVITA Medical to the FDA addresses various questions and incorporates data from in-house testing to support the PMA supplement for RECELL GO™.
Jim Corbett is the Chief Executive Officer of AVITA Medical.
The expected product launch date for RECELL GO™ is May 31, 2024.
